 Autoimmune-associated macrophage activation syndrome MAS, also known as secondary hemophagocytic lymphohistiocytosis HLH, is a rapidly progressing life-threatening disease. VP16 Etoposide is a well-known standard therapy, but is associated with substantial adverse effects, especially myelosuppression and infections , while steroids and ciclosporin CSA are not always efficient in this disease. 